
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci is poised for success with their pioneering approach of using artificial intelligence to discover and develop novel biologics. Their lead candidate, ABS-201, has shown promising results in treating hair loss and has the potential to enter the endometriosis market. While the company faces typical risks for a development-stage biotech, their strong partnerships, impressive technology platform, and unique business model make them a strong investment opportunity for long-term growth.
Bears say
Absci is a clinical-stage biotechnology company reliant on external financing and partnerships, with a lead drug that targets the competitive AGA and endometriosis markets with no guarantee of market share. There is a risk of delays due to dependence on third-party suppliers, and while Absci's platform and drug have preclinical validation, their clinical data is not expected until 2026 and 2027, respectively, leaving them far behind their competitors.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares